Rationale: Early mortality in intracerebral hemorrhage (ICH) is due to hematoma volume (HV) expansion, and there are no effective treatments available other than reduction in blood pressure. Tranexamic acid (TXA) a hemostatic drug that is widely available and safe can be a cost-effective treatment for ICH, if proven efficacious.
Hypothesis: Administration of TXA in ICH patients when given within 4.
Guillain-Barré syndrome (GBS) is the most common acute immune-mediated polyneuropathy characterized by symmetrical weakness of limbs and hyporeflexia or areflexia. Familial occurrence of GBS is rare, and only 42 patients from 20 families have been reported so far. Majority of them are from European countries.
View Article and Find Full Text PDF